Melanie Senior
Biopharma Reporter and Science Writer at Freelance
Biopharma writer (Nature Bio, IN VIVO, EY Life Sci.); runner & twitter schizo
Articles
-
2 weeks ago |
insights.citeline.com | Melanie Senior
Pharma’s Dance With Trump Risks Distracting From Longer-Term Threats09 Jun 2025Industry is trying to side-step President Trump’s tariff- and price-curbing policy proposals. It may do better facing up to enduring R&D productivity and drug affordability challenges.
-
Mar 3, 2025 |
nature.com | Melanie Senior
Oncology dealmaking fell sharply in 2024, in terms of overall value and number of deals. The ~$90 billion worth of cancer-focused licensing and merger and acquisition (M&A) transactions in 2024 represented a roughly 50% drop from the prior year, according to DealForma (Fig. 1). But 2023’s numbers were inflated by one particularly large deal: Pfizer’s $43 billion acquisition of Seagen.
-
Dec 12, 2024 |
nature.com | Melanie Senior
Merger and acquisition activity is at a seven-year low in 2024 as buyers digest prior deals and US election jitters delayed further spending. Expect a pick-up in 2025.
-
Dec 8, 2024 |
insights.citeline.com | Melanie Senior
Biopharma Plumps Pipeline With Healthy Weight Loss Candidates 09 Dec 2024 • By Melanie SeniorDespite the stellar success of the class so far, biotech is now looking past GLP-1s to more tolerable, sustainable approaches to obesity.
-
Nov 24, 2024 |
insights.citeline.com | Melanie Senior
Radiopharmaceutical Strategies Begin To Take Shape As Field Rolls Into 202525 Nov 2024 • By Melanie SeniorRadioligand therapies offer a resistance-proof mechanism that complements immuno-therapies and other drug classes. No wonder oncology players continue to pile in.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 750
- Tweets
- 275
- DMs Open
- No
Countdown to @BiotechCH hangout where I join biotech top brass including @daphnezohar @JSchimmer_E @LifeSciVC et al to talk M&A, financing…and some regulatory data points (expanded in forthcoming @NatureBiotech)
Dodgy data AND a 56k price tag? Really? Just as the pharma industry rep was recovering. Shame, because it could well be an important advance but it hasn’t yet proven that. Biogen says it is “driven to address patient needs” ... not sure this approval and price tag reflects that.
What Happens If The Confirmatory Clinical Trial For Biogen’s Alzheimer’s Drug Fails? https://t.co/NI3THwrVxF via @forbes
#InvestinBiotech 'Twas a good year, 2020, at least from the perspective of investment into biotech - UK, US, China and elsewhere. Great work @BIA_UK; glad to be involved. Look out for more @NatureBiotech shortly on the global funding picture.